Going Past the Data for Temozolomide
journal contributionposted on 2012-06-27, 00:00 authored by J. Lee Villano, Nathalie Letarte, Linda R. Bressler
The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC‐NCIC CE.3) trial and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences on length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length than in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.
Publisher Statement© 2012 by Springer Verlag, Cancer Chemotherapy and Pharmacology The original publication is available at www.springerlink.com DOI: 10.1007/s00280-011-1796-4